UNIVERSITY OF WASHINGTON

U.S. life expectancy is recovering to 2019 levels but lags behind similar countries due to bad habits and health disparities. By 2050, it's projected to increase modestly, with states' progress varying by policies and healthcare access. Urban and wealthier states fare better, highlighting the impact of social policies on health outcomes.

BRUKINSA reduces progression/death risk by 71% in CLL patients vs. bendamustine-rituximab, with a 5-year follow-up showing 75.8% PFS. Sonrotoclax with BRUKINSA shows 99% ORR in treatment-naïve CLL, no progression in 320 mg cohort. BGB-16673 shows promise in resistant CLL and B-cell malignancies. BeiGene leads in CLL/SLL treatment advancements.

In 2024, UW Medicine highlighted Rick Steves' prostate cancer journey, David Baker's Nobel Prize in Chemistry, psilocybin therapy for COVID-19 emotional distress, ADHD research, infectious disease studies, Dr. Rotonya Carr's liver disease treatment comments, and Dr. Michael Copass' memorial service.

Yahoo uses AI for article takeaways, which may not always match content. Loyal, a biotech startup, is developing LOY-002, a drug to extend dogs' healthy lifespan, potentially benefiting humans. Expected by 2025, it targets age-related metabolic changes. The Dog Aging Project explores rapamycin's effects on canine health, aiming to inform human longevity.

Scientists are testing drugs like LOY-002 and rapamycin to extend dogs' lives, potentially benefiting human longevity. Research could also offer insights into women's health, though translating findings to humans remains challenging.

Loyal, a biotech company, is developing LOY-002, a beef-flavored pill to extend dogs' lives by up to a year, targeting FDA approval by 2025. The Dog Aging Project is testing rapamycin for similar effects, potentially extending dogs' lives by three years. Both projects aim to translate findings into human longevity benefits, leveraging dogs' shorter lifespans for faster research outcomes.

Research into extending dogs' lives with drugs like LOY-002 and rapamycin could also benefit human longevity, offering insights into age-related diseases and healthspan extension.

A study in The Lancet Psychiatry estimates 1 in 127 individuals worldwide had autism in 2021, making it a top 10 health issue for youth under 20. The rise in autism rates is attributed to improved detection methods, with males affected more than females. Early diagnosis and tailored services are crucial for autistic individuals across their lifespan.

The Transdermal Drug Delivery Pipeline Report, 2024 Update, offers comprehensive insights into pipeline products, development stages, clinical trials, and key companies shaping the transdermal drug delivery market.